We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · August 26, 2019

Cost Effectiveness of Abiraterone vs Docetaxel in the Treatment of Hormone-Naïve Prostate Cancer

Urologic Oncology: Seminars & Original Investigations

 

Additional Info

Disclosure statements are available on the authors' profiles:

Urologic Oncology: Seminars & Original Investigations
Cost Effectiveness of Abiraterone Versus Docetaxel in the Treatment of Metastatic Hormone-Naïve Prostate Cancer
Urol. Oncol 2019 Aug 06;[EPub Ahead of Print], C Ramamurthy, EA Handorf, AF Correa, JR Beck, DM Geynisman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading